-
AstraZeneca gets back to growth, but can it hit $40B by 2023? CEO says yes—again
fiercepharma
November 11, 2018
AstraZeneca CEO Pascal Soriot has repeatedly said his company would finally get back on the upswing in the second half of this year, and he’s put skeptics to rest with strong third-quarter numbers. Now, he’s doubling down on an even more ambitious promise
-
AstraZeneca to sell drug rights to Covis Pharma in $371m deal
pharmaceutical-technology
November 10, 2018
AstraZeneca has agreed to divest its rights for Alvesco (ciclesonide), Omnaris and Zetonna (ciclesonide) medicines to Swiss speciality pharmaceutical firm Covis Pharma in a deal valued up to $371m.
-
Foamix publishes top line phase III results for rosacea drug
pharmaceutical-technology
November 10, 2018
Clinical stage dermatology-focused Foamix Pharmaceuticals has announced top line results from a phase III study into its FMX103, which is a 1.5% minocycline foam indicated for moderate-to-severe papulopustular rosacea.
-
Foamix publishes top line phase III results for rosacea drug
pharmaceutical-technology
November 10, 2018
Clinical stage dermatology-focused Foamix Pharmaceuticals has announced top line results from a phase III study into its FMX103, which is a 1.5% minocycline foam indicated for moderate-to-severe papulopustular rosacea.
-
Novartis division Sandoz recalls one lot of blood pressure drug
expressbpd
November 10, 2018
The drug is made by China’s Zhejiang Huahai Pharmaceutical. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan.
-
FDA highlights record-breaking number of generic drug approvals in October
worldpharmanews
November 10, 2018
Today, the U.S. Food and Drug Administration is providing a summary of the generic drug approval actions for the month of October 2018 as part of its efforts to improve patient access to high-quality, lower cost, safe and effective medicines.
-
FDA highlights record-breaking number of generic drug approvals in October
worldpharmanews
November 10, 2018
Today, the U.S. Food and Drug Administration is providing a summary of the generic drug approval actions for the month of October 2018 as part of its efforts to improve patient access to high-quality, lower cost, safe and effective medicines.
-
FDA approves Pfizer's lung cancer drug
biospectrumasia
November 07, 2018
This indication is approved under accelerated approval based on tumor response rate and duration of response
-
US approves first-in-class flu drug
pharmatimes
November 01, 2018
The US Food and Drug Administration has approved Roche/Shionogi & Co’s Xofluza for the treatment of acute uncomplicated flu, opening the door to the first new antiviral with a...
-
HHS Secretary Alex Azar responds to pharma sector’s criticism over Medicare pricing plan
pharmafile
October 31, 2018
US Health and Human Services (HHS) Secretary Alex Azar responded to industry criticism on Friday after big pharma warned that Trump’s initiative, aimed at lowering the prices .....